Dendrogenix doses first patient in Phase IIa with DX243 for age-related hearing loss
119
Posted on : 03-06-2026 | News Dendrogenix today announced that the first patient has been dosed in the Phase IIa clinical trial evaluating DX243 in patients with age-related hearing loss, also known as presbycusis. This milestone represents a major step forward in the development of DX243, a potentially first-in-class pharmacological…



